Non-Allergic Eosinophilic Asthma
關閉
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Non-Allergic Eosinophilic Asthma
FB918 is a fully-human antibody specifically targeting interleukin 33 (IL-33). It is discovered and screened from Oneness-owned antibody library and currently under pre-clinical development. FB918 regulates several cytokines signaling that induces asthma by inhibiting the binding of IL-33 to the ST2 receptor. According to literatures, IL-33 plays as a critical mediator in asthma and inflamed lung tissues. It is also a novel target bring promising future treatment as many global pharma companies are exploring its potential in different indications.
FB918 is under pre-clinical development
The treatment of non-allergic eosinophilic asthma is still in unmet medical needs. The increase in the number of type 2 innate lymphocytes (ILC2) in such patients will cause the eosinophils to mature and migrate after being stimulated by IL-33 secreted from epithelial cells, leading to disease onset. According to market analysis reports, the market size of asthma was 18 billion USD and expects to reach 26 billion USD in 2027
| Research Code | Therapeutic Area | Indication | Pre-Clinical | Phase I | Phase II | Phase III | NDA | Market | More |
|---|
FB918 is a first-in-class antibody targeting the interleukin 33 (IL-33) for non-allergic eosinophilic asthma. It has been discovered and developed from Oneness-owned antibody library
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?